2
Oct
2025
Cartography Secures $67M for T-cell Engager for Colorectal Cancer (and a Platform, Too)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2025
Finding New Targets for Cancer Drugs: Kevin Parker on The Long Run
Kevin Parker is today’s guest on The Long Run. Kevin is the co-founder and CEO of South San Francisco-based Cartography Biosciences. The company is using multi-omic tools to map out which targets are specifically expressed on cancer cells. The idea is to find new, precise targets that antibody drugs can aim for. Cartography got started during the pandemic, raised a... Read More